Idorsia Future Growth
Future criteria checks 2/6
Idorsia's earnings are forecast to decline at 22.6% per annum while its annual revenue is expected to grow at 28.8% per year. EPS is expected to grow by 10.8% per annum.
Key information
-22.6%
Earnings growth rate
10.8%
EPS growth rate
Biotechs earnings growth | 27.8% |
Revenue growth rate | 28.8% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 22 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 456 | -161 | N/A | -219 | 4 |
12/31/2025 | 261 | -349 | -379 | -354 | 6 |
12/31/2024 | 135 | -407 | -549 | -531 | 2 |
3/31/2024 | 141 | -56 | -504 | -498 | N/A |
12/31/2023 | 152 | -298 | -639 | -629 | N/A |
9/30/2023 | 185 | -374 | -751 | -739 | N/A |
6/30/2023 | 126 | -814 | -874 | -859 | N/A |
3/31/2023 | 113 | -843 | -889 | -871 | N/A |
12/31/2022 | 97 | -828 | -886 | -859 | N/A |
9/30/2022 | 48 | -887 | -868 | -836 | N/A |
6/30/2022 | 44 | -810 | -788 | -756 | N/A |
3/31/2022 | 34 | -728 | -719 | -678 | N/A |
12/31/2021 | 35 | -635 | -621 | -590 | N/A |
9/30/2021 | 36 | -520 | -542 | -515 | N/A |
6/30/2021 | 27 | -499 | -513 | -491 | N/A |
3/31/2021 | 74 | -429 | -419 | -409 | N/A |
12/31/2020 | 72 | -445 | -374 | -365 | N/A |
9/30/2020 | 70 | -450 | -379 | -367 | N/A |
6/30/2020 | 69 | -451 | -417 | -400 | N/A |
3/31/2020 | 22 | -507 | -478 | -459 | N/A |
12/31/2019 | 24 | -494 | -481 | -462 | N/A |
9/30/2019 | 61 | -460 | -479 | -461 | N/A |
6/30/2019 | 61 | -459 | -445 | -430 | N/A |
3/31/2019 | 61 | -414 | -404 | -391 | N/A |
12/31/2018 | 61 | -386 | -367 | -353 | N/A |
9/30/2018 | 209 | -213 | -81 | -63 | N/A |
6/30/2018 | 203 | -165 | -39 | -25 | N/A |
12/31/2017 | 190 | -17 | N/A | 115 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDIAZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IDIAZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IDIAZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IDIAZ's revenue (28.8% per year) is forecast to grow faster than the UK market (3.7% per year).
High Growth Revenue: IDIAZ's revenue (28.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IDIAZ's Return on Equity is forecast to be high in 3 years time